Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

Launched by REGINA ELENA CANCER INSTITUTE · Mar 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how the cancer treatment lenvatinib works in male and female patients with a type of thyroid cancer called differentiated thyroid cancer, particularly in those whose cancer does not respond to standard iodine treatment. The main goal of the study is to find out if there are differences in safety and side effects between men and women taking this medication. Researchers will also look at how well the treatment works for both genders, including how long patients live without the cancer worsening and how long they respond to the treatment.

To be eligible for this trial, participants must be adults aged 18 or older who have been diagnosed with iodine-refractory differentiated thyroid cancer and are willing to sign a consent form agreeing to participate. During the study, participants will receive lenvatinib and will be monitored for any side effects and overall effectiveness of the treatment. The trial aims to better understand how gender affects treatment outcomes, which could help improve care for everyone with this type of cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with refractory iodine DTC treated with lenvatinib
• • Signed written informed consent
• Exclusion Criteria:
• • - Age \< 18 years